Skip to main content

Advertisement

SpringerLink
Log in

Assessment of the efficacy of polyclonal intravenous immunoglobulin G (IVIG) against the infectivity of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

The response to treatment of severe methicillin-resistant Staphylococcus aureus (MRSA) infections with the traditional antibiotics is sometimes unsatisfactory and multiple antibiotic resistance is common. Adjuvant therapy such as intravenous immunoglobulin G (IVIG) could possibly be helpful in the treatment of such infections. The effect of IVIG on the capacity of human neutrophils to phagocytose and kill MRSA was investigated in vitro using the MTT assay and measuring the production of reactive oxygen species (ROS) and nitric oxide (NO). The efficiency of IVIG in neutralizing α-hemolysin and coagulase of MRSA was also assessed. The capability of IVIG in the treatment and prevention of MRSA infections was also evaluated in a murine peritonitis model. IVIG significantly enhanced (p < 0.01) the killing of MRSA by neutrophils at all concentrations tested (0.1–5 mg/ml) by 30–80 % of control values. It significantly (p < 0.01) increased the level of NO production in a dose-dependent manner, giving up to 60 μM at 5 mg/ml. The ROS level significantly increased (p < 0.01) in the presence of IVIG. In addition, IVIG significantly reduced the hemolytic activity of MRSA 10-fold and its coagulation capabilities by 50 %. When tested in vivo, groups receiving IVIG via tail vein infusion showed no significant improvement in their survival. Only when delivered to the same site of infection did IVIG show an improvement in the survival of mice (n = 80). These results could pave the way for a better understanding of the mechanism of action of IVIG and suggest its clinical potential as an adjuvant preventive and therapeutic agent against life-threatening infections caused by MRSA and other bacteria.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Rossi F, Bellon B, Vial MC, Druet P, Kazatchkine MD (1991) Beneficial effect of human therapeutic intravenous immunoglobulins (IVIg) in mercuric-chloride-induced autoimmune disease of Brown-Norway rats. Clin Exp Immunol 84(1):129–133

    Article  PubMed  CAS  Google Scholar 

  2. El-Azhary R (2005) Intravenous immunoglobulin in dermatology. Egypt Wom Dermatol 2(2):4

    Google Scholar 

  3. Misra N, Bayary J, Dasgupta S, Ephrem A, Huyen JP, Delignat S, Hassan G, Caligiuri G, Nicoletti A, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV (2005) Intravenous immunoglobulin and dendritic cells. Clin Rev Allergy Immunol 29(3):201–205

    Article  PubMed  CAS  Google Scholar 

  4. Unkeless JC, Shen Z, Lin CW, DeBeus E (1995) Function of human Fc gamma RIIA and Fc gamma RIIIB. Semin Immunol 7(1):37–44

    Article  PubMed  CAS  Google Scholar 

  5. Laupland KB, Kirkpatrick AW, Delaney A (2007) Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med 35(12):2686–2692. doi:10.1097/01.CCM.0000295312.13466.1C

    Article  PubMed  CAS  Google Scholar 

  6. Bittner D, Enk A (2008) Intravenous immunoglobulins. In: Gaspari AA, Tyring SK (eds) Clinical and basic immunodermatology, vol 3. Springer London, London, pp 605–614

    Chapter  Google Scholar 

  7. Späth PJ (1999) Structure and function of immunoglobulins. Sepsis 3(3):197–218

    Article  Google Scholar 

  8. Ishii N, Hashimoto T, Zillikens D, Ludwig RJ (2009) High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin Rev Allergy Immunol 38(2–3):186–195. doi:10.1007/s12016-009-8153-y

    Google Scholar 

  9. Peterlana D, Puccetti A, Simeoni S, Tinazzi E, Corrocher R, Lunardi C (2005) Efficacy of intravenous immunoglobulin in chronic idiopathic pericarditis: report of four cases. Clin Rheumatol 24(1):18–21. doi:10.1007/s10067-004-0959-7

    Article  PubMed  CAS  Google Scholar 

  10. Barekzi NA, Felts AG, Poelstra KA, Slunt JB, Grainger DW (2002) Locally delivered polyclonal antibodies potentiate intravenous antibiotic efficacy against gram-negative infections. Pharm Res 19(12):1801–1807

    Article  PubMed  CAS  Google Scholar 

  11. Norrby-Teglund A, Kaul R, Low DE, McGeer A, Andersson J, Andersson U, Kotb M (1996) Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 64(12):5395–5398

    PubMed  CAS  Google Scholar 

  12. Darenberg J, Söderquist B, Normark BH, Norrby-Teglund A (2004) Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis 38(6):836–842. doi:10.1086/381979

    Article  PubMed  CAS  Google Scholar 

  13. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP Jr, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C; Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology (2006) Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117(4 Suppl):S525–S553. doi:10.1016/j.jaci.2006.01.015

    Article  PubMed  CAS  Google Scholar 

  14. DeLeo FR, Otto M (2008) An antidote for Staphylococcus aureus pneumonia? J Exp Med 205(2):271–274. doi:10.1084/jem.20080167

    Article  PubMed  CAS  Google Scholar 

  15. Noto MJ, Fox PM, Archer GL (2008) Spontaneous deletion of the methicillin resistance determinant, mecA, partially compensates for the fitness cost associated with high-level vancomycin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 52(4):1221–1229. doi:10.1128/AAC.01164-07

    Article  PubMed  CAS  Google Scholar 

  16. Matouskova I, Janout V (2008) Current knowledge of methicillin-resistant Staphylococcus aureus and community-associated methicillin-resistant Staphylococcus aureus. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 152(2):191–202

    Article  PubMed  Google Scholar 

  17. Goldstein F, Perutka J, Cuirolo A, Plata K, Faccone D, Morris J, Sournia A, Kitzis MD, Ly A, Archer G, Rosato AE (2007) Identification and phenotypic characterization of a beta-lactam-dependent, methicillin-resistant Staphylococcus aureus strain. Antimicrob Agents Chemother 51(7):2514–2522. doi:10.1128/AAC.00040-07

    Article  PubMed  CAS  Google Scholar 

  18. Memmi G, Filipe SR, Pinho MG, Fu Z, Cheung A (2008) Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother 52(11):3955–3966. doi:10.1128/AAC.00049-08

    Article  PubMed  CAS  Google Scholar 

  19. D’Agata EM, Webb GF, Horn MA, Moellering RC Jr, Ruan S (2009) Modeling the invasion of community-acquired methicillin-resistant Staphylococcus aureus into hospitals. Clin Infect Dis 48(3):274–284

    Article  PubMed  Google Scholar 

  20. Nguyen HM, Graber CJ (2010) Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? J Antimicrob Chemother 65(1):24–36. doi:10.1093/jac/dkp377

    Article  PubMed  CAS  Google Scholar 

  21. Dalla Valle C, Pasca MR, De Vitis D, Marzani FC, Emmi V, Marone P (2009) Control of MRSA infection and colonisation in an intensive care unit by GeneOhm MRSA assay and culture methods. BMC Infect Dis 9:137. doi:10.1186/1471-2334-9-137

    Article  PubMed  Google Scholar 

  22. Han G, Martinez LR, Mihu MR, Friedman AJ, Friedman JM, Nosanchuk JD (2009) Nitric oxide releasing nanoparticles are therapeutic for Staphylococcus aureus abscesses in a murine model of infection. PLoS One 4(11):e7804. doi:10.1371/journal.pone.0007804

    Article  PubMed  Google Scholar 

  23. Behera B, Das A, Mathur P, Kapil A, Gadepalli R, Dhawan B (2009) Tigecycline susceptibility report from an Indian tertiary care hospital. Indian J Med Res 129(4):446–450

    PubMed  Google Scholar 

  24. Henson PM, Oades ZG (1975) Stimulation of human neutrophils by soluble and insoluble immunoglobulin aggregates. Secretion of granule constituents and increased oxidation of glucose. J Clin Invest 56(4):1053–1061. doi:10.1172/JCI108152

    Google Scholar 

  25. Foster TJ (2005) Immune evasion by staphylococci. Nat Rev Microbiol 3(12):948–958. doi:10.1038/nrmicro1289

    Article  PubMed  CAS  Google Scholar 

  26. Palazzolo-Ballance AM, Reniere ML, Braughton KR, Sturdevant DE, Otto M, Kreiswirth BN, Skaar EP, DeLeo FR (2008) Neutrophil microbicides induce a pathogen survival response in community-associated methicillin-resistant Staphylococcus aureus. J Immunol 180(1):500–509

    PubMed  CAS  Google Scholar 

  27. Li M, Cha DJ, Lai Y, Villaruz AE, Sturdevant DE, Otto M (2007) The antimicrobial peptide-sensing system aps of Staphylococcus aureus. Mol Microbiol 66(5):1136–1147. doi:10.1111/j.1365-2958.2007.05986.x

    Article  PubMed  CAS  Google Scholar 

  28. Sharma A, Tripathi AK, Kalra OP, Chakrabarty AK (2000) Impaired function of neutrophils in uraemic patients. Natl Med J India 13(3):121–124

    PubMed  CAS  Google Scholar 

  29. Winterbourn CC, Hampton MB, Livesey JH, Kettle AJ (2006) Modeling the reactions of superoxide and myeloperoxidase in the neutrophil phagosome: implications for microbial killing. J Biol Chem 281(52):39860–39869. doi:10.1074/jbc.M605898200

    Article  PubMed  CAS  Google Scholar 

  30. Sahoo G, More T, Singh VK (2000) Evaluation of oxygen-dependent immunodefences of the polymorphonuclear cells of some tropical ruminants. Vet Res Commun 24(8):505–515

    Article  PubMed  CAS  Google Scholar 

  31. Wheeler MA, Smith SD, García-Cardeña G, Nathan CF, Weiss RM, Sessa WC (1997) Bacterial infection induces nitric oxide synthase in human neutrophils. J Clin Invest 99(1):110–116. doi:10.1172/JCI119121

    Article  PubMed  CAS  Google Scholar 

  32. Mastroeni P, Vazquez-Torres A, Fang FC, Xu Y, Khan S, Hormaeche CE, Dougan G (2000) Antimicrobial actions of the NADPH phagocyte oxidase and inducible nitric oxide synthase in experimental salmonellosis. II. Effects on microbial proliferation and host survival in vivo. J Exp Med 192(2):237–248

    Article  PubMed  CAS  Google Scholar 

  33. Montgomery RR, Lusitani D, de Boisfleury Chevance A, Malawista SE (2002) Human phagocytic cells in the early innate immune response to Borrelia burgdorferi. J Infect Dis 185(12):1773–1779. doi:10.1086/340826

    Google Scholar 

  34. Geller DA, Billiar TR (1998) Molecular biology of nitric oxide synthases. Cancer Metastasis Rev 17(1):7–23

    Article  PubMed  CAS  Google Scholar 

  35. Allen RC (1977) Evaluation of serum opsonic capacity by quantitating the initial chemiluminescent response from phagocytizing polymorphonuclear leukocytes. Infect Immun 15(3):828–833

    PubMed  CAS  Google Scholar 

  36. Easmon CS, Cole PJ, Williams AJ, Hastings M (1980) The measurement of opsonic and phagocytic function by Luminol-dependent chemiluminescence. Immunology 41(1):67–74

    PubMed  CAS  Google Scholar 

  37. Ono Y, Ito T, Watanabe T, Koshio O, Tansho S, Ikeda T, Kawakami S, Miyazawa Y (2004) Opsonic activity assessment of human intravenous immunoglobulin preparations against drug-resistant bacteria. J Infect Chemother 10(4):234–238. doi:10.1007/s10156-004-0325-3

    PubMed  CAS  Google Scholar 

  38. Bubeck Wardenburg J, Schneewind O (2008) Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 205(2):287–294. doi:10.1084/jem.20072208

    Article  PubMed  Google Scholar 

  39. Yanagisawa C, Hanaki H, Natae T, Sunakawa K (2007) Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin. J Infect Chemother 13(6):368–372. doi:10.1007/s10156-007-0551-6

    Google Scholar 

  40. Aarestrup F. M. SNL, Sordillo L. M. (1994) Ability of Staphylococcus aureus coagulase genotypes to resist neutrophil bactericidal activity and phagocytosis. Infect Immun 62(12):5679–5682

  41. Lotsu DK, Imamura T, Takamine F (1995) Current status of antimicrobial susceptibility in MRSA isolates typed by coagulase and phage typing in Okinawa. Acta Med Okayama 49(2):81–89

    PubMed  CAS  Google Scholar 

  42. Jonsson P, Lindberg M, Haraldsson I, Wadström T (1985) Virulence of Staphylococcus aureus in a mouse mastitis model: studies of alpha hemolysin, coagulase, and protein A as possible virulence determinants with protoplast fusion and gene cloning. Infect Immun 49(3):765–769

    PubMed  CAS  Google Scholar 

  43. Werdan K, Pilz G (1996) Supplemental immune globulins in sepsis: a critical appraisal. Clin Exp Immunol 104(Suppl 1):83–90

    PubMed  Google Scholar 

  44. Cross AS (1995) Intravenous immunoglobins (IVIGs) to prevent and treat infectious diseases. Adv Exp Med Biol 383:123–130

    Article  PubMed  CAS  Google Scholar 

  45. Douzinas EE, Pitaridis MT, Louris G, Andrianakis I, Katsouyanni K, Karmpaliotis D, Economidou J, Syfras D, Roussos C (2000) Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins. Crit Care Med 28(1):8–15

    Article  PubMed  CAS  Google Scholar 

  46. Werdan K (2001) Intravenous immunoglobulin for prophylaxis and therapy of sepsis. Curr Opin Crit Care 7(5):354–361

    Article  PubMed  CAS  Google Scholar 

  47. Sriskandan S, Ferguson M, Elliot V, Faulkner L, Cohen J (2006) Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother 58(1):117–124. doi:10.1093/jac/dkl173

    Article  PubMed  CAS  Google Scholar 

  48. Weisman LE, Lorenzetti PM (1989) High intravenous doses of human immune globulin suppress neonatal group B streptococcal immunity in rats. J Pediatr 115(3):445–450

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Faculty of Pharmacy and Biotechnology, German University in Cairo, Main Entrance Al Tagamoaa Al Khames, New Cairo City, Egypt

    N. Farag, L. Mahran, K. Abou-Aisha & M. El-Azizi

Authors
  1. N. Farag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Mahran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Abou-Aisha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. El-Azizi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. El-Azizi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Farag, N., Mahran, L., Abou-Aisha, K. et al. Assessment of the efficacy of polyclonal intravenous immunoglobulin G (IVIG) against the infectivity of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo. Eur J Clin Microbiol Infect Dis 32, 1149–1160 (2013). https://doi.org/10.1007/s10096-013-1861-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-013-1861-5

Keywords

Search

Navigation